Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting 0.5â€“1% of the worldwide population. Whilst predominantly causing chronic pain and .
The prognosis of patients with RA–ILD has been the subject of several studies since 1993 and most papers reported a mean survival from diagnosis of 3 years.
The type of ILD affects mortality risk. Different factors may affect survival rates including RA disease duration, time of ILD diagnosis and extent of the disease, .
Keywords: Rheumatoid arthritis, Interstitial lung disease, Mycophenolate mofetil, Cyclophosphamide,. in RA, and mean survival from diagnosis is about.
Interstitial lung disease (ILD) is associated with rheumatoid arthritis (RA);. of pulmonary disease usually postdates the onset of joint symptoms by only 0â€“5 yr .
Rheumatoid Arthritisâ€“associated Interstitial Lung Disease: Radiologic. . In addition, the UIP pattern in RA-ILD is associated with significantly shortened survival .
Background There is little evidence base to guide clinicians in the management of patients with rheumatoid arthritis (RA) related interstitial lung disease (ILD).
Acute exacerbation has a serious impact on the survival of patients with rheumatoid arthritis-associated interstitial lung disease. Given its retrospective study .
Rheumatoid arthritis (RA) is a systemic autoimmune disorder with a variety of. There was no difference in survival between UIP-pattern RA-ILD subjects and .